Episode Details

Healthcare innovation has been one of the biggest investment stories of the year. Psychedelic biotech is moving from a speculative theme to one attracting major pharmaceutical capital, while the cannabis industry continues to make progress following the conclusion of the DEA's Schedule III hearings.

AdvisorShares' Dan Ahrens joins AlphaNooner to look at what's driving both themes, where investors may be underappreciating the opportunity in small- and micro-cap healthcare innovators, and what could come next.

AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories shaping what comes next.

Watch the full video on YouTube: https://www.youtube.com/watch?v=jAxtkc9tLRQ

Follow AdvisorShares (@advisorshares) on YouTube, X, LinkedIn, Instagram and Facebook.